Screener
TG Therapeutics TGTX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's debt-to-equity?
- TG Therapeutics (TGTX) reported debt-to-equity of 1.2× in Q2 2026.
- How has TG Therapeutics's debt-to-equity changed year-over-year?
- TG Therapeutics's debt-to-equity increased by 36.1% year-over-year, from 0.9× to 1.2×.
- What is the long-term trend for TG Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), TG Therapeutics's debt-to-equity has grown at a 37.1% compound annual growth rate (CAGR), from 0.1× to 0.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about TG Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude